ABSTRACT We have developed an in vitro system, using embryonic chicken tibiae grown in a serum-free medium, which exhibits simultaneous bone formation and resorption. Tibiae from 8-day embryos increased in mean (±SD) length (4.0 ± 0.4 to 11.0 ± 0.3 mm) and dry weight (0.30 ± 0.04 to 0.84 ± 0.04 mg) during 12 days in vitro. There was increased incorporation of [3H]proline into hydroxyproline (120 ± 20 to 340 ± 20 cpm/mg of bone per 24 hr) as a measure of collagen synthesis, as well as a 62 ± 5% increase in total calcium and 45Ca taken up as an indication of active mineralization. A physiologic concentration (1 pM) of parathyroid hormone was found to stimulate bone resorption over control levels in this system. Parathyroid hormone stimulated the release of [3H]hydroxyproline from the bone shafts but not from the cartilage ends, indicating the specificity of theresponse. With 1 pM parathyroid hormone we observed an acute inhibition of bone formation, followed (after 12-16 hr) by a chronic stimulation of bone formation during the 12-day incubation. Both mineral uptake and matrix formation were enhanced at approximately the same rate during the 12-day incubation. The chronic enhancement of formation required parathyroid hormone only for the initial 8-10 hr of incubation. These results could be explained by the production or release ofa factor from bone to stimulate formation in response to the acute increase in resorption-a "coupling factor." Indeed, dialyzed culture medium conditioned by actively resorbing bones stimulated bone formation over controls when added to organ cultures at a 1:20 dilution. The factor is larger than 12,000 daltons as determined by dialysis. The factor is specific for the bone shaft and did not affect the cartilage ends. Work directed toward a better understanding of the regulation of bone metabolism has shown that bone formation and bone resorption are coupled in vivo (1). This coupling occurs even in some disease states (e.g., hyper-and hypoparathyroidism, Paget disease, and acromegaly) (2). Detailed knowledge of the regulatory mechanism of coupling could lead to better understanding of the problems of metabolic bone disease. Studies toward this end from our laboratory have in the past relied predominantly on in vivo experiments (3, 4) . Although a large number of investigators have examined bone metabolism in vitro (5-9), none of these studies involved a chemically defined system in which simultaneously enhanced bone formation and resorption could be demonstrated. We have developed such an in vitro system and describe the details herein.
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We have utilized this coupled system to study the effects of parathyroid hormone (PTH) on bone metabolism in vitro in an attempt to clarify what appears to be a disagreement in the literature concerning these effects. The acute effect in vivo is reported to be the stimulation of bone resorption and inhibition of bone formation (10, 11) . Chronic in vivo treatment of young growing rats with PTH results in an increase in formation and resorption (4) and a net gain in bone volume (10) (11) (12) . We have recently obtained similar results in vitro for the acute and chronic effects of PTH (13) . Moreover, as reported earlier for resorption in rat bone (14) , the in vitro effect of PTH in our system is an inductive one in that the continued presence of PTH is unnecessary for bone resorption and bone formation to be stimulated for several days (13) .
Our hypothesis for these findings is that some type of inherent bone regulation not requiring the continued presence of PTH could explain the apparently divergent effects of PTH on bone formation. Accordingly, the ability of PTH to induce bone resorption under chronic conditions could enhance the synthesis or release of a substance that subsequently was stimulatory for bone formation. This is consistent with the concept of an osteogenic coupling factor that could be involved in the local regulation of endosteal bone volume as is observed in vivo (3, 4) . The in vitro system described herein was used to test this hypothesis.
MATERIALS AND METHODS
Embryonic Bones. Fertilized Rhode Island Red chicken eggs (Fors Farms, Tacoma, WA) were incubated at 370C for 8 days, at which time the embryos were removed from the eggs. The tibiae and femora were isolated by blunt dissection and debrided of soft tissue by gently rolling the bones on dry sterile gauze. Isolated bones were rinsed three times in Hanks' balanced salt solution and then transferred to lens paper rafts, two bones per raft, with 0.5 ml of medium (13, 15) .
Culture Conditions. The embryonic bones were cultured in vitro at 370C in a moist atmosphere of5% CO2 in air. The basic medium for control incubation conditions was Fitton-Jackson modified BGJb medium (GIBCO) containing added potassium phosphate (4.8 1010 becquerels). After removal from the culture medium, the bones were rinsed thoroughly in three changes of balanced salt solution to remove exchangeable radioactivity. The cartilage ends were dissected free from the shaft of the bone and combined in one test tube; the shaft was placed in another. The samples were extracted for 5 min with 95% ethanol and then for 5 min with diethyl ether, air dried, and weighed on a microbalance. The bone shafts and cartilage ends were hydrolyzed overnight in 0.2 ml of 6 M HCl at 100'C; then 'Ca or [3H]proline and [3H]hydroxyproline radioactivity were determined in a liquid scintillation spectrometer.
In order to quantify the radioactivity in proline and hydroxyproline, they were separated on silica gel thin-layer plates (Polygram Sil G, Brinkmann) by using distilled water as the solvent. Proline and hydroxyproline were separated from each other, as well as from arginine and glutamine, the other metabolites of proline that could have been radioactively labeled. The amino acids were located by reaction with ninhydrin in acetone- (13) . The recoveries of radioactivity from the gel were >90%. The same basic procedure was used to determine [3H]proline and [3H]hydroxyproline released into the culture medium in the resorption experiments, except that an equal volume of 10 M HCI was added to the medium for the hydrolysis step.
PTH. Bovine parathyroid extract (PTE; 100 units/ml; Lilly)
or synthetic bovine PTH ffragment 1-34; 5700 units/mg (manufacturer's assay); Beckman, Palo Alto, CA] was diluted in balanced salt solution or BGJb medium to obtain the final concentration indicated in the respective experiments. A specific activity for PTE of 1800 units/mng was assumed, for the calculation of molarity (Lilly). Thus, the 1 pM PTE used in these experiments was equivalent to 0.3 milliunits/ml, final concentration. Conditioned Medium. Tibiae and femora from 8-day embryonic chickens were stimulated to active resorption by a 12-hr exposure to 1 nM PTH. The bones were rinsed several times in balanced salt solution and then incubated in control medium for 24 hr to utilize or remove all PTH (13, 14) . At this point, the bones were placed in fresh control medium which was then collected and replaced with fresh medium each day for 5-6 days. The collected medium was dialyzed (12,000-14,000 dalton exclusion limit dialysis tubing; Spectra/Por 2; Spectrum Medical Industries, Los Angeles; prepared by extensive washing with distilled H20) against 10 mM phosphate-buffered saline (pH 7.4) and then incubated with 8-day tibiae in fresh control medium at a dilution of 1:20 fbr 10 days. The medium was replaced every second day. Medium from bones without PTH pretreatment was used for the control. The bones were cultured with [3H]proline for the last 24 hr and then processed as described above to quantify the radioactivity.
Determination of 40Ca. Total calcium (40Ca) content of the bones was quantified by atomic absorption spectrometry of an aliquot of the HCI hydrolysate in a Perkin-Elmer model 403 (17) . RESULTS The in vitro organ culture system was evaluated for growth of the embryonic bones during control incubation conditions. The mean (±SD) length and dry weight of the femora and tibiae increased linearly to approximately 300% of the starting values after 12 days of incubation (4.0 ± 0.4 to 11.0 + 0.3 mm; 0.30 ± 0.04 to 0.84 ± 0.04 mg).
Growth of the embroyonic bones in vitro under control incubation conditions involved an increase in mineral content as well as formation of new matrix. A linear relationship was found between 40Ca content and length of the bones (slope, 0.54) as well as between 40Ca content and dry weight ofthe bones (slope, 6.76). Both relationships showed statistically significant correlations (r = 0.97; P <0.001).
We next examined the effect of a physiologic concentration of PTE on bone resorption in this system. The results showed a significant simulation of bone resorption with 1 pM PTE (a physiologic concentration for humans) over bones incubated in control medium, as assessed by the release of previously incorporated [3H]hydroxyproline into the culture medium (Fig.   1) .
To examine the response of bone formation to PTE in our system we tested the effect of different concentrations of PTE added to the control medium. We were able to show enhanced bone formation, as assessed by [3H]hydroxyproline content, with a physiologic concentration (1 pM) of PTE (Fig. 2) . At 0.01 to 1 nM added PTE there was inhibition ofbone formation. We used 1 pM PTE in the remainder of the studies on enhanced bone formation because this concentration induced apparently maximal stimulation of matrix formation over control bones within the range of concentrations tested.
Because the resorptive effect of PTH is reportedly on bone and not cartilage (18, 19) , we tested to determine if this difference manifested itself in our in vitro system. At 1 pM, PTE significantly enhanced bone growth in the shaft over control values (Fig. 3A) , but did not significantly increase growth ofthe epiphyseal cartilage ends (Fig. 3B) cpm/jig of bone; n = 8; P < 0.001]. Again there was no effect of 1 pM PTE on the cartilage ends compared with bones incubated for 12 days in the absence ofPTE (PTE-treated vs. control: 125 ± 17 vs. 142 ± 26 cpm/,ug of cartilage; n = 8).
In order to determine whether the effect of PTE was solely enhancement of collagen synthesis or included increasing the mineral content of the bones as well, we examined the effect of 1 pM PTE both on total calcium (40Ca) content and 45Ca up- [3Hlhydroxyproline in the medium was measured. Each point is the mean ± SD for 8-12 bones. For difference from control: *, P <0.001; **, P <0.05 (Student's t test). take by the bones. The amount of45Ca accumulated in the bones was increased by the addition of 1 pM PTE to the culture medium during 12-day incubation (PTE-treated vs. control: 115 ± 12 vs. 264 ± 37 cpm/,g of bone; n = 8; P < 0.001). Moreover, the total calcium content of the bones was also increased significantly by 1 pM PTE over the values from control bones (Fig. 4) , indicating that the increased 45Ca uptake was not simply the result of isotope exchange.
The results described thus far demonstrate that our in vitro --system is active in bone resorption as well as in matrix formation and mineralization. Furthermore, these processes were stim- Effect of PTE on 40Ca content of embryonic chicken tibiae in organ culture. Tibiae from 8-day embryos were incubated in the presence (x) or absence (e) of 1 pM PTE for the times indicated. Each point is the mean ± SD for six to eight bones. For difference from controls: *, P < 0.05; **, P < 0.001 (Student's t test).
ulated by the addition of 1 pM PTE, even though the acute effect (16 hr) of PTE was an inhibition and not a stimulation of formation (Fig. 5) . The direct effect of PTE is this system could explain the acute decrease in bone formation; the enhanced bone formation (after 16 hr) could be a counterregulatory response of bone itself to the increase in resorption. In support of this hypothesis we had shown previously that the continued presence of PTE was unnecessary for this response (13) .
To examine if this compensatory phenomenon was mediated by a factor(s) produced by bone, conditioned medium was collected from cultures of PTH-stimulated (1 nM), actively resorbing, embryonic tibiae (and medium from control bones, not treated with PTH) and added to cultures of freshly isolated 8-day embryonic tibiae. Both bone dry weight and [3H]hydroxyproline content, as indices of bone formation, were increased upon addition of a 1:20 dilution of the dialyzed conditioned medium (Table 1) . Inclusion of the factor(s) in the retentate after dialysis suggests that it is larger than 12,000-14,000 daltons. Furthermore, no growth-stimulating activity was seen in the dialysate (20) . A more precise size estimate, 75,000 dal- Experiments were performed as described in Figs. 1 and 2 for resorption and formation, with or without 1 pM PTE, for 16 hr. The data are shown as mean ± SD for six to eight bones. For both, for difference from controls, P < 0.001 (Student's t test). Tibiae from 8-day chicken embryos were cultured for 10 days in control medium or medium conditioned by PTH-stimulated bone resorption.
[3H]proline was added to the medium for the last 24 hr of incubation. Data are shown as means ± SD (n = 6-8). * For difference from control, P < 0.001 (Student's t test).
tons, has been obtained by chromatography ofthe coupling factor on Sephadex G-75 (21) .
The factor(s) is apparently specific for the bone shaft because it did not affect the growth of the cartilage ends of the bones ( Table 1 ). The amount ofprotein (ifcoupling factor is a protein) released into the medium and subsequently assayed in this system (35 ng/ml more than control medium protein added) is consistent with coupling factor being a specific entity. It is in the concentration range of growth stimulators and not just as added protein per se.
Resorption, not the resorptive agent, is responsible for the coupling factor because results similar to those for PTH stimulation of coupling factor production have also been observed with 1 nM 1,25-dihydroxyvitamin D3 (21 Moreover, in further support of coupling factor as a specific entity in conditioned medium is the fact that PTH-mediated inhibition offormation could be overcome by adding exogenous coupling factor (control, 350 + 42 pmol of [3H]hydroxyproline; 1 nM PTE-treated, 297 ± 32; 1 nM PTE-treated + 1:10 coupling factor, 395 ± 28; n = 8).
DISCUSSION
In our system, simultaneous bone formation and resorption has been demonstrated in a serum-free, chemically defined medium. The bone growth probably represents both endochondral and appositional activity because the bones grow in weight and diaphyseal diameter as well as in length. These data in conjunction with the existence ofa significant correlation (r = 0.97; P < 0.001) between mineral content and bone growth suggest that matrix formation and mineralization are coordinately regulated in this system. These results extend the finding by Ramp and Neuman (22) that 10-day embryonic chicken tibiae showed mineralization in vitro during a 4-day culture period. The bones appear grossly normal morphologically; histologically they show osteoblasts, osteoclasts, and mineralized matrix as found by Biggers et al. (23) under similar incubation conditions.
We have shown that mineral accretion parallels hydroxyproline increase, indicating that the bones were mineralizing as well as forming new matrix. This strongly supports our conclusion that we are observing bone formation and not aberrant matrix formation. These results also do not support simple marrow fibrosis or periosteal membrane proliferation as alternatives to explain the [3H]proline incorporation data because these processes could not account for the huge increase in dry weight of the PTE-treated bones over that of the control bones. Moreover, histologically the bones did not show marrow fibrosis.
Another possible explanation for the data is that the [3H]hydroxyproline was not incorporated into matrix collagen but rather existed inside the cells as the free amino acid or as soluble procollagen molecules. Brand and Raisz (16) reported earlier that most of the [3H]hydroxyproline incorporated into rat bone under their culture conditions was found in matrix within 6 hr. We have confirmed this by autoradiographic studies (unpublished data). Moreover, Chen and Raisz (24) reported that ". . . collagenase-digestible radioactivity in dialyzed (rat) bone and medium was constant from 6 to 24 h indicating that no large amount of this material was degraded to dialyzable molecules." Because our chicken bones were rapidly growing and the time points at which bone formation was assessed greatly exceeded 6 hr, we would argue that the results obtained are not significantly influenced by any soluble [3H]hydroxyproline.
The influence of changes in amino acid uptake or in the size of the intracellular nonradioactive proline pool was minimized by having 3.4 mM proline in the medium. This should have been ample to saturate the pool and suppress the endogenous synthesis of proline by the cells (19) .
In the bone resorption experiment, essentially all of the released [3H]hydroxyproline must have come from matrix collagen because, after labeling with [3H]proline for 48 hr, the bones were incubated for 24 hr in medium without [3H]proline to allow sufficient time for any soluble [3H]hydroxyproline to be incorporated into matrix collagen.
We have used this system to examine two important differences (i.e., dose and temporal responses) between the bone formation and bone resorption responses to added PTH. We found increased bone resorption in response to a physiologic dose (1 pM) of PTH (or 0.3 milliunit of PTE per ml). Studies by others utilized much higher concentrations ofPTE (0.5 unit/ ml) or PTH (0.1 unit/ml) to obtain bone resorption in vitro (25, 26) . With 1 pM PTE we observed an acute inhibition of bone formation followed by a chronic enhancement of bone formation; higher concentrations ofPTE (0.01-1 nM) caused a chronic inhibition of bone formation (Fig. 2) . This apparent biphasic response of bone formation to PTE at different concentrations supports earlier reports that net bone growth is related to the concentration of PTH administered (11, 12) . The use of high concentrations of PTE could easily explain the failure of previous in vitro studies to detect bone growth with added PTE (25) .
The stimulation of formation by PTE is quite specific in our system as shown by a comparison of the cartilage and bone data (Fig. 3) . The bone shaft responded to PTE, whereas the cartilage ends were unaffected by the hormone.
Normal bone growth requires mineralization as well as collagen synthesis, and this system shows concurrent, possibly coordinated, mineral and matrix depositions. In our system, mineral uptake as well as collagen synthesis was enhanced at approximately the same rate during 12-day incubation after acute PTE treatment of the bones.
The fact that PTH fragment 1-34 gave results similar to those obtained with PTE indicates that there is no aberrant factor present in the PTE preparations to which the results could be attributed. Others have reported that fragment 1-34 PTH was capable of producing the same effects on bone as bovine PTH 1-84, suggesting that the total PTH molecule is unnecessary for its activity on bone (26, 27) .
The results ofour experiments suggest that PTH alone is sufficient to stimulate bone metabolism and that other hormones or vitamin D metabolites are unnecessary. Furthermore, as reported by Raisz et al. (14) and verified in our previous work (13) , even PTH need not be present during the entire incubation period. Taken together, these results suggest that PTH may have a direct as well as an indirect effect on bone metabolism. Although the acute, presumably direct, effect we have seen is one of inhibited formation and enhanced resorption, the results of short-term exposure to PTH do show stimulation of both these processes later in a 12-day incubation period. The latter results are consistent with an indirect effect of PTH on bone formation as might be expected in a coupled system. Although this coupling could explain the anabolic effects observed with PTH treatment, we are aware that PTH could also have an anabolic effect on bone metabolism unrelated to coupling.
Further support of an indirect effect of PTH and, consequently, evidence for local regulation of bone metabolism are shown in Table 1 . This suggests the production of a nondialyzable factor(s)-a "coupling factor"-by actively resorbing bones.
That this factor may be related to bone resorption is consistent with the finding that increased resorption preceded formation when the system was stimulated with PTH (13) . Moreover, our demonstration of a coupling factor could explain, in part, the apparently conflicting reports in the literature about the effects of PTH on bone metabolism.
Increased resorption could trigger synthesis/release of coupling factor which could then overcome the resorptive action of PTH in bone metabolism to effect a net increase in bone formation. The finding that higher concentrations of PTH inhibit bone formation does not invalidate the hypothesis because the continued presence ofa high concentration of PTH could somehow interfere with the action of coupling factor, the new effect being a loss of bone. Preliminary evidence supporting this suggestion indicates that the PTH-mediated inhibition offormation can be overcome by adding exogenous coupling factor.
In accordance with this hypothesis for local regulation is our previous work showing that there does not appear to be a consistent relationship between the coupled increase in bone formation and serum levels of systemic calcium-regulating hormones (i.e., PTH, 1,25-dihydroxyvitamin D3, or calcitonin) (4). Instead, a locally produced coupling factor could explain the finding that coupling is locally regulated (3, 4) . Furthermore, preliminary evidence indicates that resorption per se and not the resorptive agent is responsible for coupling factor. Results similar to those reported herein for PTH stimulation ofcoupling factor production have also been observed with 1 nM 1,25-dihydroxyvitamin D3.
In order to understand the mechanism of action of coupling factor, a knowledge ofits source during active resorption would be helpful. It is possible that the coupling factor(s) may be released from matrix as it is resorbed by PTH-activated osteoclasts. This would require that coupling factor(s) be produced by osteoblasts as the matrix is deposited initially. Alternatively, the PTH-activated osteoclasts may be producing or releasing the coupling factor(s) that is' subsequently stimulatory for osteoblasts.
